Pegaptanib for myopic choroidal neovascularization in a young patient

Case Report



The treatment of choroidal neovascularization (CNV) due to myopic degeneration can include laser photocoagulation, photodynamic therapy, corticosteroids, and subretinal surgery. We report a case of a young patient with myopic CNV refractive to laser photocoagulation, photodynamic therapy, and intravitreal triamcinolone acetonide treated with intravitreal pegaptanib injections.


Interventional case report. The medical chart of a 36-year-old female treated with intravitreal pegaptanib injections was reviewed for changes in visual acuity on the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart, CNV leakage on fluorescein angiography, and adverse events reported.


ETDRS visual acuity improved from counting fingers (CF) to 20/40 in the right eye after five, 6-weekly pegaptanib injections.


This is the sentinel case of US Food and Drug Administration (FDA) approved pegaptanib usage for non-wet macular degeneration via an Investigational New Drug application (Title 21, Code of Federal Regulations part 132). Pegaptanib appears to be effective in treating myopic CNV refractive to laser photocoagulation, photodynamic therapy, and intravitreal triamcinolone acetonide.


Myopic choroidal neovascularization Pegaptanib sodium 


  1. 1.
    Yoshida T, Ohno-Matsui K, Ohtake Y, Takashima T, Futagami S, Baba T, Yasuzumi K, Tokoro T, Mochizuki M (2002) Long-term visual prognosis of choroidal neovascularization in high myopia. A comparison between age groups. Ophthalmology 109(4):712–719PubMedCrossRefGoogle Scholar
  2. 2.
    Chan W-M, Lam DSC, Wong T-H, Lai TYY, Kwok AKH, Tam BSM, Li KKW (2003) Photodynamic therapy with verteporfin for subfoveal idiopathic choroidal neovascularization: one-year results from a prospective case series. Ophthalmology 110(12):2395–2402PubMedCrossRefGoogle Scholar
  3. 3.
    Macular Photocoagulation Study Group (1982) Argon laser photocoagulation for idiopathic neovascularization. Results of a randomized clinical trial. Arch 101(9):1358–1361Google Scholar
  4. 4.
    Gragoudas ES, Adamis AP, Cunningham ET Jr,Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351(27):2805–2816PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  1. 1.Retina Institute of HawaiiHonoluluUSA

Personalised recommendations